重症监护室中创伤性脑损伤患者疾病轨迹的临床描述指标(CENTER-TBI):一项多中心观察性队列研究
该研究基于CENTER-TBI前瞻性观察性队列,纳入65个中心ICU收治的1728例成年创伤性脑损伤患者,应用基于概率图模型混合与马尔可夫链扩展的新型聚类方法分析前7天数据,发现血糖变异及脑生物标志物是区分疾病轨迹的主要临床描述指标,且轨迹聚类可改善对死亡和不良结局的预测。
要点
- 血糖变异(每日血糖最高值与最低值之差)和脑生物标志物(S100B、NSE、NFL、tau、UCH-L1、GFAP)是区分ICU中创伤性脑损伤患者疾病轨迹的主要临床描述指标。
- 将患者所属疾病轨迹聚类与IMPACT模型变量联合分析,可改善对死亡和不良结局(GOS-E≤4)的预测。
- 作者认为血糖变异是最重要的可能区分ICU疾病轨迹的临床描述指标,应指导进一步研究。
核心结论
- ICU入住首日数据并非创伤性脑损伤患者疾病轨迹的唯一临床描述指标。
- 通过分析时间变量,血糖变异被识别为最重要的可能区分ICU疾病轨迹的临床描述指标,应指导进一步研究。
- 脑损伤生物标志物(S100B、NSE、NFL、tau、UCH-L1和GFAP)也是随时间变化的重要临床描述指标,提示它们在未来临床实践中可能重要。
研究设计与样本
- 研究使用协作欧洲神经创伤效果研究(CENTER-TBI)前瞻性观察性队列研究的数据。
- 纳入65个CENTER-TBI参与中心(从大型学术医院到小型乡村医院)ICU收治的18岁及以上创伤性脑损伤患者。
- 收集每例患者的伤前数据和损伤特征、入院时临床特征、人口学资料、生理参数、实验室指标、脑生物标志物(UCH-L1、S100B、tau、NFL、GFAP和NSE)以及ICU入住前7天颅内压降低治疗信息。
- 采用基于概率图模型混合与马尔可夫链扩展的新型聚类方法识别可能区分疾病轨迹的临床变量,并分析聚类与扩展格拉斯哥结局量表(GOS-E)的关系。
- 2014年12月19日至2017年12月17日,CENTER-TBI核心数据集共招募4509例创伤性脑损伤患者,其中1728例符合本分析条件。
主要发现
- 血糖变异(定义为每日血糖最高值与最低值之差)和脑生物标志物(S100B、NSE、NFL、tau、UCH-L1和GFAP)被一致发现是ICU中创伤性脑损伤患者疾病轨迹的主要临床描述指标(即贡献于区分聚类的主要变量)。
- 将患者所属疾病轨迹聚类与IMPACT模型变量一起作为预测因子分析,对死亡和不良结局(二分类GOS-E≤4)的预测均得到改善。
临床怎么用
- 作者认为血糖变异是最重要的可能区分ICU疾病轨迹的临床描述指标,应指导进一步研究。
- 作者认为脑损伤生物标志物(S100B、NSE、NFL、tau、UCH-L1和GFAP)也是随时间变化的重要临床描述指标,提示它们在未来临床实践中可能重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with traumatic brain injury are a heterogeneous population, and the most severely injured individuals are often treated in an intensive care unit (ICU). The primary injury at impact, and the harmful secondary events that can occur during the first week of the ICU stay, will affect outcome in this vulnerable group of patients. We aimed to identify clinical variables that might distinguish disease trajectories among patients with traumatic brain injury admitted to the ICU. METHODS: We used data from the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) prospective observational cohort study. We included patients aged 18 years or older with traumatic brain injury who were admitted to the ICU at one of the 65 CENTER-TBI participating centres, which range from large academic hospitals to small rural hospitals. For every patient, we obtained pre-injury data and injury features, clinical characteristics on admission, demographics, physiological parameters, laboratory features, brain biomarkers (ubiquitin carboxy-terminal hydrolase L1 [UCH-L1], S100 calcium-binding protein B [S100B], tau, neurofilament light [NFL], glial fibrillary acidic protein [GFAP], and neuron-specific enolase [NSE]), and information about intracranial pressure lowering treatments during the first 7 days of ICU stay. To identify clinical variables that might distinguish disease trajectories, we applied a novel clustering method to these data, which was based on a mixture of probabilistic graph models with a Markov chain extension. The relation of clusters to the extended Glasgow Outcome Scale (GOS-E) was investigated. FINDINGS: Between Dec 19, 2014, and Dec 17, 2017, 4509 patients with traumatic brain injury were recruited into the CENTER-TBI core dataset, of whom 1728 were eligible for this analysis. Glucose variation (defined as the difference between daily maximum and minimum glucose concentrations) and brain biomarkers (S100B, NSE, NFL, tau, UCH-L1, and GFAP) were consistently found to be the main clinical descriptors of disease trajectories (ie, the leading variables contributing to the distinguishing clusters) in patients with traumatic brain injury in the ICU. The disease trajectory cluster to which a patient was assigned in a model was analysed as a predictor together with variables from the IMPACT model, and prediction of both mortality and unfavourable outcome (dichotomised GOS-E ≤4) was improved. INTERPRETATION: First-day ICU admission data are not the only clinical descriptors of disease trajectories in patients with traumatic brain injury. By analysing temporal variables in our study, variation of glucose was identified as the most important clinical descriptor that might distinguish disease trajectories in the ICU, which should direct further research. Biomarkers of brain injury (S100B, NSE, NFL, tau, UCH-L1, and GFAP) were also top clinical descriptors over time, suggesting they might be important in future clinical practice. FUNDING: European Union 7th Framework program, Hannelore Kohl Stiftung, OneMind, Integra LifeSciences Corporation, and NeuroTrauma Sciences.
引用
- Åkerlund CAI, Holst A, Bhattacharyay S, et al. Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study. Lancet Neurol. 2023. PMID: 37977157. doi:10.1016/S1474-4422(23)00358-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。